Connect your AI

Veracyte VCYT Operating Lease Liability Payments - 2025 (Lessee)

Operating Lease Liability Payments - 2025 (Lessee) at other companies

Guardant HealthGH

——

Natera, Inc.NTRA

——

Bio-Rad LaboratoriesBIO

——

Idexx LaboratoriesIDXX

——

AbbottABT

——

Other financials

Income statement

Revenue$139.1M+21.5%

Gross profit$101.2M+27.2%

Operating income$22.6M+680%

Net income$28.7M+307%

EPS (diluted)$0.35+289%

Balance sheet

Cash & equivalents$264.8M+41.0%

Total debt$39.3M-22.1%

Total equity$1.3B+12.5%

Total assets$1.4B+9.2%

Cash flow

Operating cash flow$35.2M+557%

CapEx$3.0M+62.8%

Free cash flow$32.3M+810%

Valuation

Market cap$4.29B+10.7%

Profitability

Gross margin70.9%+2.9pp

Operating margin14.3%+9.2pp

Net margin16.2%+9.1pp

FCF margin28.7%+11.7pp

Returns & leverage

Return on equity6.9%+4.1pp

Debt / equity0×0.0×

Current ratio9.3×+4.2×

Where this comes from

Reported directly by Veracyte in its filing.

Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour.

The official record: Veracyte’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Veracyte's operating lease liability payments - 2025 (lessee).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Veracyte's operating lease liability payments - 2025 (lessee)?: Veracyte (VCYT) reported operating lease liability payments - 2025 (lessee) of $7.06M in Q1 2026.
How has Veracyte's operating lease liability payments - 2025 (lessee) changed year-over-year?: Veracyte's operating lease liability payments - 2025 (lessee) decreased by 14.4% year-over-year, from $8.25M to $7.06M.